KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Receivables - Net Receivables - Other Receivables Refunds Shares Outstanding Shares Outstanding

Ratios

Takeda Pharmaceutical (TAK) EBIAT (2025)

Takeda Pharmaceutical has reported EBIAT over the past 1 years, most recently at $913.6 million for Q4 2025.